Diabetes mellitus is a condition in which the pancreas no longer produces enough insulin or when cells stop responding to the insulin that is produced, so that glucose in the blood cannot be absorbed into the cells of the body. Symptoms include frequent urination, lethargy, excessive thirst, and hunger. The treatment includes changes in diet, oral medications, and in some cases, daily injections of insulin.
Researchers at Columbia University Medical Center link blood sugar to normal cognitive aging – Maintaining blood sugar levels, even in the absence of disease, may be an important strategy for preserving cognitive health, suggests a study published by researchers at Columbia University Medical Center (CUMC).
In patients with type 2 diabetes, 6-month treatment with a low?glycemic index diet resulted in moderately lower HbA1c levels compared with a high?cereal fiber diet. – Persons with type 2 diabetes who had a diet high in low-glycemic foods such as nuts, beans and lentils had greater improvement in glycemic control and risk factors for coronary heart disease than persons on a diet with an emphasis on high-cereal fiber, according to a study in the December 17 issue of JAMA.
Long term use of oral diabetic drugs doubles the risk of fractures in women with type 2 diabetes. – Long term use of a popular class of oral diabetic drugs doubles the risk of fractures in women with type 2 diabetes, revealed by researchers at the Wake Forest University School of Medicine and the University of East Anglia.
Diabetes medications (rosiglitazone – Avandia) in same class carry different risks of heart failure, death – Older adults who take the diabetes medication rosiglitazone appear to have a higher risk of death and heart failure than those taking the related medication pioglitazone, according to a report in the November 24 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
Genetic screening no better than traditional risk factors for predicting type 2 diabetes, Value of screening may improve as more risk genes identified. – Screening for a panel of gene variants associated with the risk for type 2 diabetes can identify adults at risk for the disorder but is not significantly better than assessment based on traditional risk factors such as weight, blood pressure and blood sugar levels.
Eli Lilly and Company donated more than 800,000 insulin vials to provide free life-saving medicine to an estimated 24,000 children over four years. – Eli Lilly and Company announced it intends to donate more than 800,000 vials of insulin to the International Diabetes Federation’s Life for a Child Program, providing free life-saving medicine to as many as 24,000 children who currently have no access to diabetes treatment.
Former Miss America Nicole Johnson Takes Action for Type 1 Diabetes Research; Promotes advance screening and clinical research available nationwide. – Diabetes in Children and Adolescents has particular urgency for former Miss America Nicole Johnson. Nicole has served as an international spokesperson for diabetes issues for more than 8 years. She has worked tirelessly promoting awareness, prevention and early detection of the hidden killer, diabetes.
US FDA Reports Nationwide Recall of Mislabeled ReliOn Insulin Syringes – The U.S. Food and Drug Administration is notifying health care professionals and patients that Tyco Healthcare Group LP (Covidien) is recalling one lot of ReliOn sterile, single-use, disposable, hypodermic syringes with permanently affixed hypodermic needles due to possible mislabeling.
In US, diabetic patients have nearly doubled their spending on drugs for the diabetes disease in last 6 years. – Because of the increased number of patients, growing reliance on multiple medications and the shift toward more expensive new medicines, the annual cost of diabetes drugs nearly doubled in only six years, rising from $6.7 billion in 2001 to $12.5 billion in 2007 according to a study in the Oct. 27, 2008, issue of the Archives of Internal Medicine.
Living Cell Technologies receives New Zealand’s Health Minister?s approval to start leading edge live cell therapy clinical trial in New Zealand for Diabetes patients. – Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY) announced that New Zealand Health Minister, the Honorable David Cunliffe, has approved an application from the company to conduct in New Zealand a Phase I/IIa clinical trial of DiabeCell?, LCT’s lead product candidate for the treatment of insulin dependent (Type 1) diabetes.
